The Cooper Companies, Inc. fell -24.9% this week.
0 indicators fired, 10 red flags hit the wire, and SP Fear sits at 59/100 (neutral). Hit rates with the usual asterisks; nothing here is advice.
- 10 EDGAR red flags filed — Kestra Medical Technologies, LTD. flagged material weakness (confirmed control failure).
- Biggest 7-day drop: The Cooper Companies, Inc. (-24.9%).
- Biggest 7-day run: Skyworks Solutions, Inc. (+22.6%).
- SP Fear Composite: 59/100 (neutral).
Indicators that fired (0)
No qualifying fires inside the 7-day window.
Red flags on the EDGAR wire (10)
- Kestra Medical Technologies, LTD. KMTSHIGH · 10-QMaterial weakness (confirmed control failure) · 1 prior episode(s) — recurringmedian ~-8% vs SPY at 63d, 66% negative
- Reformation Inc. REFHIGH · 10-QMaterial weakness (confirmed control failure) · 1 prior episode(s) — recurringmedian ~-8% vs SPY at 63d, 66% negative
- Navan, Inc. NAVNHIGH · 10-QMaterial weakness (confirmed control failure) · 1 prior episode(s) — recurringmedian ~-8% vs SPY at 63d, 66% negative
- Radiant Logistics, INC RLGTLOW · 10-KMaterial weakness (confirmed control failure) · 7 prior episode(s) — chronicmedian ~-8% vs SPY at 63d, 66% negative
- Benitec Biopharma Inc. BNTCLOW · 10-KMaterial weakness (confirmed control failure) · 3 prior episode(s) — chronicmedian ~-8% vs SPY at 63d, 66% negative
- Immersion CORP IMMRLOW · 10-QMaterial weakness (confirmed control failure) · 4 prior episode(s) — chronicmedian ~-8% vs SPY at 63d, 66% negative
Biggest 7-day moves
- +22.6%
- +14.4%
- +12.0%
- +12.0%
- +11.9%
- -24.9%
- -19.9%
- -19.1%
- -17.4%
- -15.1%
New pundit calls (0)
No new qualifying calls from the tracked pods this week.
Where the composites sit
What the paid crew saw
Trader's live red-flag radar surfaced these the morning each filing hit EDGAR, with the validated per-tier historical drawdown attached. You're reading the public slice.
The data chat (Analyst 100/mo, Trader unlimited) will answer "what else co-fired with these this week?" against the validated universe.
The weekly digest, emailed when the data warrants it. No ads, no spam, one-click unsubscribe.
Not investment advice. Every figure here is a historical pattern with caveats — sample size, multiple testing, and survivorship all apply. Reread the methodology before treating any single line as actionable.